Financial Survey: Beauty Health (SKIN) vs. The Competition

Beauty Health (NASDAQ:SKINGet Rating) is one of 216 public companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Beauty Health to related companies based on the strength of its risk, institutional ownership, valuation, earnings, dividends, analyst recommendations and profitability.

Earnings & Valuation

This table compares Beauty Health and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Beauty Health $260.09 million -$375.11 million -3.96
Beauty Health Competitors $1.15 billion $84.66 million -518.90

Beauty Health’s competitors have higher revenue and earnings than Beauty Health. Beauty Health is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Insider and Institutional Ownership

72.0% of Beauty Health shares are held by institutional investors. Comparatively, 51.2% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 34.3% of Beauty Health shares are held by company insiders. Comparatively, 14.5% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Beauty Health and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Beauty Health -117.84% -0.01% N/A
Beauty Health Competitors -748.20% -64.90% -19.61%

Analyst Ratings

This is a breakdown of current recommendations for Beauty Health and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Beauty Health 0 1 9 0 2.90
Beauty Health Competitors 1297 4625 8016 221 2.51

Beauty Health presently has a consensus target price of $26.11, indicating a potential upside of 94.13%. As a group, “Surgical & medical instruments” companies have a potential upside of 53.59%. Given Beauty Health’s stronger consensus rating and higher possible upside, research analysts plainly believe Beauty Health is more favorable than its competitors.

Volatility & Risk

Beauty Health has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Beauty Health’s competitors have a beta of 1.12, suggesting that their average share price is 12% more volatile than the S&P 500.

Summary

Beauty Health beats its competitors on 10 of the 13 factors compared.

Beauty Health Company Profile (Get Rating)

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.

Receive News & Ratings for Beauty Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beauty Health and related companies with MarketBeat.com's FREE daily email newsletter.